PDS BIOTECHNOLOGY CORPORATION PDSB 深 沪
等待开盘 12-29 09:30:00 美东时间
0.9042
+0.011
+1.22%
华盛通- 最 高0.93
- 今 开0.91
- 成交量 66.80万股
- 最 低 0.884
- 昨 收 0.8933
- 总市值 4776.48万
- 52周最高 2.20
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 0.703
- 委 比 -93.59%
- 总股本 5282.55万
- 历史最高 17.85
- 量 比 1.90
- 振 幅 5.15%
- 历史最低 0.615
- 每 手 1
- 风险率 0.26%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Athira Pharma (NASDAQ:ATHA) stock increased by 30.6% to $5.4 during Th...
12-18 20:05
PDS Biotech Secures New Japan Patent Granting Broad Protection For PDS0101, Extending Global IP Coverage Into The 2040s
New Patent Grants Broad Composition Claims for PDS0101Previously Granted Patent Protections and Anticipated Market Exclusivity Provide Protection for PDS0101 in the United States into the 2040sPRINCETON, N.J., Dec. 09,
12-09 21:08
美股大行评级 | 安捷伦科技、Keysight、先科电子获多家大行上调目标价；摩根大通下调亿航智能评级至"中性"，目标价下调至13美元
今日重点评级关注：HC Wainwright & Co.：维持BiomX"买入"评级，目标价从15美元升至26美元；Clear Street：维持Diversified Energy"买入"评级，目标价从23美元升至25美元
11-26 10:07
B. Riley Securities Maintains Buy on PDS Biotechnology, Lowers Price Target to $3
B. Riley Securities analyst Kalpit Patel maintains PDS Biotechnology (NASDAQ:PDSB) with a Buy and lowers the price target from $5 to $3.
11-26 02:14
美股大行评级 | 思科、On Holding、派拓网络等获多家机构上调目标价；Circle 遭富国、德银等多家机构下调目标价
今日重点评级关注：HC Wainwright & Co.：维持PDS Biotechnology"买入"评级，目标价从13美元升至15美元；HC Wainwright & Co.：维持PepGen Inc."买入"评级，目标价从18美元升至20美元
11-14 10:43
PDS Biotechnology Q3 EPS $(0.19) Beats $(0.22) Estimate
PDS Biotechnology (NASDAQ:PDSB) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.22) by 13.64 percent. This is a 34.48 percent increase over losses of $(0.29) per share from
11-13 20:31
Earnings Scheduled For November 13, 2025
Companies Reporting Before The Bell • Edgewell Personal Care (NYSE:EPC) is proj...
11-13 19:11
A Look Ahead: PDS Biotechnology's Earnings Forecast
PDS Biotechnology (NASDAQ:PDSB) is preparing to release its quarterly earnings ...
11-13 01:03
PDS Biotechnology Announces $5.3M Registered Direct Offering Of 5.8M Shares With Warrants At A Combined Price Of $0.91
PDS Biotechnology Corporation (NASDAQ:PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced that it has
11-12 04:35
PDS Biotechnology Presents Clinical, Translational Data On Investigational Hpv16-Targeted Immunotherapy Pds0101 And Its Novel, Investigational Immunocytokine Pds01ADC
PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers, today announced positive clinical
11-10 21:34
